Evidence map›Paper›PMID 33853869›Full record

ArticleJournal of clinical microbiology2021

An HIV Diagnostic Testing Algorithm Using the cobas HIV-1/HIV-2 Qualitative Assay for HIV Type Differentiation and Confirmation.

Dana Duncan, John Duncan, Bastian Kramer, Alex Y Nilsson, Betiel Haile, Ann Butcher, Shikha Chugh, Paul Baum, Grace M Aldrovandi, Stephen Young and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Estimating the Economic Consequences of Leveraging the Novel cobas HIV-1/HIV-2 Qualitative Nucleic Acid Amplification Test in Routine HIV Testing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Dana DuncanRoche Molecular Systems, Pleasanton, California, USA.
John DuncanRoche Molecular Systems, Pleasanton, California, USA.
Bastian KramerRoche Molecular Systems, Basel, Switzerland.
Alex Y NilssonRoche Molecular Systems, Basel, Switzerland.
Betiel HaileRoche Molecular Systems, Pleasanton, California, USA.
Ann ButcherRoche Molecular Systems, Pleasanton, California, USA.
Shikha ChughRoche Molecular Systems, Pleasanton, California, USA.
Paul BaumRoche Molecular Systems, Pleasanton, California, USA.
Grace M AldrovandiDepartment of Pediatrics, University of California, Los Angeles, Los Angeles, California, USA.
Stephen YoungTriCore Reference Laboratories, Albuquerque, New Mexico, USA.
Ann K AveryMetroHealth, Cleveland, Ohio, USA.
Karen TashimaThe Miriam Hospital, Providence, Rhode Island, USA.
Alexandra ValsamakisRoche Molecular Systems, Pleasanton, California, USA.
Joseph D YaoDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Ming ChangDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Robert W CoombsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Materials Systems (United States) · USRoche (Switzerland) · CHUniversity of Washington · USApplied Research Associates (United States) · USMayo Clinic · USMetroHealth · USMiriam Hospital · USUniversity of California, Los Angeles · US

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI042853NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) diagnostic testing algorithms recommended by the Centers for Disease Control involve up to three tests and rely mostly on detection of viral antigen and host antibody responses. HIV-1 p24 antigen/HIV-1/HIV-2 antibody-reactive specimens are confirmed with an immunochromatographic HIV-1/HIV-2 antibody differentiation assay, and negative or indeterminate results from the differentiation assay are resolved by an HIV-1-specific nucleic acid amplification test (NAT). The performance of a proposed alternative algorithm using the cobas HIV-1/HIV-2 qualitative NAT as the differentiation assay was evaluated in subjects known to be infected with HIV-1 (

Indexed as

HIV-1HIV InfectionsAlgorithmsDiagnostic Tests, RoutineHIV-2HumansRNA, ViralSensitivity and SpecificityRNA, ViraldiagnosisHIV-1HIV-2PCRtesting algorithm

Identifiers

PMID33853869
PMCPMC8218759
OpenAlexW3157022584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.